TCGA-OR-A5J2-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.430
- WNT_BETA_CATENIN_SIGNALING+0.376
- HEDGEHOG_SIGNALING+0.352
- MITOTIC_SPINDLE+0.329
- PANCREAS_BETA_CELLS+0.251
- UV_RESPONSE_DN+0.242
- PROTEIN_SECRETION+0.235
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.218
- APICAL_JUNCTION+0.198
- PI3K_AKT_MTOR_SIGNALING+0.173
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.499
- INTERFERON_ALPHA_RESPONSE-0.378
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.369
- DNA_REPAIR-0.367
- MYC_TARGETS_V1-0.354
- FATTY_ACID_METABOLISM-0.338
- P53_PATHWAY-0.331
- MYC_TARGETS_V2-0.316
- ADIPOGENESIS-0.299
- INTERFERON_GAMMA_RESPONSE-0.275
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9ca22f6c-326b-4844-8e7d-fb076c7e1067 | — | — | 0.842 |
| 2 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.793 |
| 3 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.777 |
| 4 | TCGA-BH-A1FH-01A-12R-A13Q-07 | — | A | 0.776 |
| 5 | TCGA-AN-A041-01A-11R-A034-07 | — | B | 0.775 |
| 6 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.774 |
| 7 | 90407c8f-6193-45c7-9f29-0783aeeab94d | — | — | 0.769 |
| 8 | TCGA-AR-A1AL-01A-21R-A12P-07 | — | A | 0.767 |
| 9 | AUR-AF94-TTP1-A-1-0-R-A741-41 | — | D | 0.757 |
| 10 | 37cb9185-9334-45cc-8afe-6aea6784aaba | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.430 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.376 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.352 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.329 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.251 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.242 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.235 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.218 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.198 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.173 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.173 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.171 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.165 | Temsirolimus | — uncovered |
| COAGULATION | 0.159 | Binimetinib | — uncovered |
| MYOGENESIS | 0.154 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.144 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.104 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.081 | Idelalisib | — uncovered |